Daily Newsletter

22 September 2023

Daily Newsletter

22 September 2023

Signal: CMR Surgical Raises $165m to continue development of surgical robot

The UK-based surgical robotics company has now raised over $1bn in funding, cementing its unicorn status.

Isaac Hanson September 22 2023

Cambridge, UK-based CMR Surgical has raised $165m in funding to continue the development of its Versius surgical robot. This latest investment brings their total raised to over $1bn, cementing the coveted unicorn status the company acquired in 2019 through a £195m (then $240m) round of Series C funding.

CMR was founded in 2014, and through numerous record-breaking funding rounds has established itself as a major competitor of US-based Intuitive Surgery, currently the market leader in surgical robotics. It claims to offer a unique surgical experience by allowing complete freedom of port placement, mimicking the way surgeons would traditionally operate, alongside a modular system small enough to fit inside any operating theatre.

Brian Hicks, Senior Medical Devices Analyst at GlobalData, explains that “Even well-established and leading robotic surgical companies like Intuitive Surgical continue to see near double-digit growth in this market overall, so investors see lots of potential in continued technological and product adoption into hospitals and integrated delivery networks.”

Versius recently passed the milestone of 15,000 surgeries and is used in over 20 countries across a range of specialisms. Alleged benefits of surgical robots include reduced strain for surgeons and decreased recovery times for patients by allowing for more widespread use of minimal access surgery (MAS).

MAS, commonly known as keyhole surgery, is a form of surgery in which the operation is performed through a series of small incisions in the body into which equipment is inserted, reducing blood loss and post-surgery pain and recovery time.

If CMR is able to continue to take market share from Intuitive Surgical, the growth potential is huge. Intuitive is currently valued at over $100bn and made more in profit last year than CMR has raised over its nine-year lifespan.

Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.

Multiple Myeloma (MM) pipeline dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close